License & Milestone Revenues was Cytokinetics’s largest product and service line in fiscal 2025, bringing in $79.35M of $88.04M (90%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2022 | FY 2023 | FY 2025 |
|---|---|---|---|---|---|---|
| Realization Of Revenue Participation Right Purchase Agreement | $87.00M | — | — | |||
| License & Milestone Revenues | $1.00M | $3.50M | $79.35M | |||
| Research & Development Revenues | — | — | — | |||
| License | — | — | — | |||
| License Revenues | — | — | — | |||
| Collaboration Revenues | $6.59M | $4.03M | $8.69M | |||
| Research & Development, Grant And Other Revenues, Net | — | — | — | |||
| Total | $94.59M | $7.53M | $88.04M |
Cytokinetics brought in $88.04M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 1,069.2% from $7.53M in fiscal 2023, the previous year with figures. License & Milestone Revenues was the largest at $79.35M (90.1%), ahead of Collaboration Revenues at $8.69M (9.9%).
Compared with fiscal 2023, the previous year with figures, License & Milestone Revenues grew 2,167.2% to $79.35M and Collaboration Revenues grew 115.5% to $8.69M.
Cytokinetics stopped reporting Realization Of Revenue Participation Right Purchase Agreement as a separate line after fiscal 2022, when it brought in $87.00M.
Bayer License Agreement was Cytokinetics’s largest revenue line in fiscal 2025, bringing in $72.40M of $87.40M (83%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2025 |
|---|---|
| Bayer License Agreement | $72.40M |
| Accounting For The License & Collaboration Agreements In China | $15.00M |
| Total | $87.40M |
Cytokinetics brought in $87.40M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. Bayer License Agreement was the largest at $72.40M (82.8%), ahead of Accounting For The License & Collaboration Agreements In China at $15.00M (17.2%).
Amgen was Cytokinetics’s largest revenue line in fiscal 2019, bringing in $13.80M of $26.90M (51%).
| Major Customers | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 |
|---|---|---|---|---|---|
| Astellas | $77.28M | $11.93M | $29.39M | $13.10M | |
| Amgen | $27.88M | $1.28M | $1.90M | $13.80M | |
| Total | $105.16M | $13.21M | $31.29M | $26.90M |
Cytokinetics brought in $26.90M from its two revenue lines in fiscal 2019, the year ended December 31, 2019. That was down 14.0% from $31.29M in fiscal 2018. Amgen was the largest at $13.80M (51.3%), ahead of Astellas at $13.10M (48.7%).
Compared with fiscal 2018, Amgen grew 626.3% to $13.80M, while Astellas fell 55.4% to $13.10M. From fiscal 2016 to 2019, combined revenue from these revenue lines fell from $105.16M to $26.90M, a compound annual decline of 36.5%. Amgen's share of the total rose from 26.5% to 51.3%.
Cytokinetics (CYTK) reports its revenue by product and service, by collaborative arrangement and arrangement other than collaborative and by major customers. In fiscal 2025, License & Milestone Revenues was its largest product and service line, bringing in $79.35M (90.1% of the total), followed by Collaboration Revenues at $8.69M (9.9%).
License & Milestone Revenues was Cytokinetics' largest product and service line in fiscal 2025, bringing in $79.35M, or 90.1% of the $88.04M total across its two product and service lines.
Bayer License Agreement was Cytokinetics' largest revenue line in fiscal 2025, bringing in $72.40M, or 82.8% of the $87.40M total across its two revenue lines.
Amgen grew faster than Astellas in fiscal 2019, up 626.3% from $1.90M to $13.80M. Astellas fell 55.4% to $13.10M.
Every figure comes from Cytokinetics' annual financial filings, as reported. Each line keeps the name Cytokinetics gives it, and years follow its fiscal calendar.
Cytokinetics' revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.